Facebook icon Twitter icon Forward icon

Canagliflozin audit examines ‘real life benefits’

An audit to compare the drug Canagliflozin in clinical trials with real life outcomes has been launched.

The aim of the Canagliflozin Audit is to ascertain whether the experience in real clinical use matches the data from phase 3 clinical trials, the Association of British Clinical Diabetologists (ABCD) said. To read more, click here

Pioneering devise approved for children

A glucose monitoring system designed to eliminate the need for routine finger pricks has been approved for the use of 4-17 year olds.

The FreeStyle® Libre Flash Glucose Monitoring System uses “innovative” sensor technology to check glucose levels. To read more, click here

Diabetes child transition document published

A blueprint for a service which bridges the gap between children and adults services has been published.

The Diabetes Transition Service Specification document sets out a “best practice model and considerations” which are to be made by commissioners who are providing services for young people with diabetes through transition as young adults. To read more, click here

Online hypo programme launched

An interactive online hypoglycaemia programme to help people with diabetes and those around them has been launched.

The Hypo Training Program has been launched by Diabetes.co.uk, which is Europe’s largest diabetes forum for people with the condition. To read more, click here

SGLT2 recommendations made over DKA


Incidents of serious diabetic ketoacidosis (DKA) cases in people who have been taking sodium-glucose co-transporter-2 (SGLT2) have been reported where people's blood sugar levels have not been as high as expected, said the European Medicines Agency (EMA).

To read more, click here.

Better sensor pump access for hypos announced

People with type 1 diabetes who experience severe hypos are being given better access to sensor-augmented pumps, it has been announced.

The National Institute for Health and Clinical Excellence (NICE) has published final diagnostics guidance recommending the MiniMed Paradigm Veo System (Medtronic) for managing blood glucose levels in some people with type 1 diabetes. To read more, click here